Abatacept til behandling af reumatoid artritis

Henrik Nielsen, Annette Hansen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

Abatacept (CTLA4Ig) is a human fusion protein which consists of a cytotoxic lymphocytic-associated type 4 antigen which is bound to the Fc part of the IgG1. Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the naïve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway.
Udgivelsesdato: 2009-Jan
Bidragets oversatte titelAbatacept in the treatment of active rheumatoid arthritis
OriginalsprogDansk
TidsskriftUgeskrift for læger
Vol/bind171
Udgave nummer4
Sider (fra-til)214-7
Antal sider4
ISSN0041-5782
StatusUdgivet - 2009

Bibliografisk note

Keywords: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunoconjugates; Immunosuppressive Agents; Treatment Outcome

Citationsformater